What is the current market size and future outlook for the gastroparesis drugs market?
The gastroparesis drugs market size has grown strongly in recent years. It will grow from $5.39 billion in 2024 to $5.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to side effects of existing treatments, gastrointestinal motility research, clinical need, patient advocacy, and regulatory support.
The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $7.2 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes, the aging population, rising awareness and diagnosis rates, increase in healthcare expenditure, and government and private funding. Major trends in the forecast period include advancements in gastroenterology, improved diagnostic techniques, technological innovations, research funding, and collaborative research efforts.
Get Your Free Sample of The Global Gastroparesis Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp
Which Market drivers have played a significant role in driving the gastroparesis drugs market?
The increasing prevalence of diabetes is expected to propel the growth of the gastroparesis drugs market going forward. Diabetes presents as a persistent health issue marked by high blood sugar levels stemming from inadequate insulin production or the body’s ineffective utilization of insulin. The increasing prevalence of diabetes is due to sedentary lifestyles, unhealthy dietary habits, genetic predisposition, urbanization, and aging populations, compounded by limited access to healthcare and rising obesity rates worldwide. Gastroparesis drugs are frequently prescribed for diabetic patients to alleviate symptoms such as nausea, vomiting, and delayed gastric emptying, common complications of diabetes affecting gastrointestinal motility. These medications aim to improve gastric function and enhance the quality of life for individuals with diabetes-related gastroparesis. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the increasing prevalence of diabetes is driving the growth of the gastroparesis drugs market.
What are the key segments within the gastroparesis drugs market?
The gastroparesis drugs market covered in this report is segmented –
1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs
2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration
5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce
Subsegments:
1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements
2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report
Which key players are shaping the gastroparesis drugs market?
Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.
Which transformative trends will shape the gastroparesis drugs market landscape?
Major companies operating in the gastroparesis drugs market are focusing on introducing innovative drugs, such as Gimoti (metoclopramide) nasal spray, to gain a competitive edge in the market. Gimoti (metoclopramide) nasal spray is a medication used to treat symptoms of gastroparesis in adults, improving stomach emptying by enhancing gastrointestinal motility. It bypasses the gastrointestinal tract and is absorbed directly into the bloodstream through the nasal mucosa. For instance, in April 2022, Evoke Pharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted new drug product exclusivity for GIMOTI (metoclopramide) nasal spray. This exclusivity gives Evoke exclusive marketing rights for three years from the original approval date under the Hatch-Waxman Act, protecting the product from generic competition.
How do regional factors impact the gastroparesis drugs market, and which region is the largest contributor?
North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Gastroparesis Drugs Market Report 2025 Offer?
The gastroparesis drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Gastroparesis drugs are medications used to manage and treat gastroparesis, a condition where the stomach’s ability to empty its contents is delayed, causing symptoms such as nausea, vomiting, and abdominal pain. These drugs typically include prokinetics to stimulate stomach motility, antiemetics to control nausea and vomiting, and medications to manage pain and other symptoms associated with the condition.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15812
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
